IFNA1 and hepatocellular carcinoma: In a systematic review of 11 studies of the effect of IFN-α and NUC therapy on the outcome of HBV infection over the previous 10 years, Sung et al (69) determined that IFN-α or NUC treatment significantly reduced the risk of developing HCC.